Tigermed Acquires Frontage Laboratories - - BioPharm International

ADVERTISEMENT

Tigermed Acquires Frontage Laboratories



Hangzhou Tigermed Consulting, a provider of outsourced clinical development services across China and the Asia Pacific, has entered a definitive agreement, subject to certain closing conditions and regulatory approval, to acquire a majority position in the ownership of Frontage Laboratories for a cash payment of $50.25 million.

Headquartered in Exton, PA, Frontage provides bioanalysis, preclinical and early phase clinical studies, drug development (CMC) services, and DMPK support for biopharmaceutical organizations. The company offers a range of services from discovery through late-stage clinical trials for new, generic, and consumer product development programs. Frontage also owns Frontage Lab (Shanghai) Co, Ltd.

Frontage will continue to operate independently. Song Li will remain CEO, and its current management team will remain in place after the transaction.

Source: Frontage Laboratories

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here